Overview
OrbiMed is an investment manager focused exclusively on the healthcare sector. OrbiMed’s predecessor
was founded in 1989, and OrbiMed is owned by Sven H. Borho, Carl L. Gordon, W. Carter Neild, Geoffrey
C. Hsu, C. Scotland Stevens, David P. Bonita, Matthew S. Rizzo, and Peter A. Thompson. As of December
31, 2023, OrbiMed managed approximately $12.1 billion on a discretionary basis on behalf of 31 clients.
This Brochure generally includes information about us and our relationships with our clients. While much
of this Brochure applies to all such clients, certain information included herein applies to specific clients
only.
OrbiMed provides discretionary investment management services to U.S. and non-U.S. public and private
funds. In providing such services, OrbiMed utilizes strategies based on evaluating pharmaceutical,
biotechnology, medical device, healthcare services and other companies in the global healthcare sector. Such
strategies generally include, within the healthcare sector and subject to the investment program of each client,
investments in the securities of U.S. and non-U.S. public and/or private companies. The descriptions set
forth in this Brochure of specific advisory services that we offer to our clients, and investment strategies
pursued and investments made by us on behalf of our clients, should not be understood to limit in any way
our investment activities. We may offer any advisory services, engage in any investment strategy and make
any investment, including any not described in this Brochure, that we consider appropriate, subject to each
client’s investment objectives and guidelines. The investment strategies we pursue are speculative and entail
substantial risks. Clients should be prepared to bear a substantial loss of capital. There can be no assurance
that the investment objectives of any client will be achieved.
Our investment decisions and advice with respect to each client will be subject to each client’s investment
objective and guidelines, as set forth in its respective offering documents. Clients are permitted to set
guidelines for their accounts which customize OrbiMed’s core strategies, including restrictions related to
sub-sector, geographic and other weightings. In providing its investment advisory services, OrbiMed
determines when and which investments will be acquired, disposed of, or exchanged on behalf of its clients
to maintain a portfolio consistent with each client’s objectives.
OrbiMed does not currently participate in any Wrap Fee Programs.